INHIBITION OF<i>PSEUDOMONAS ÆRUGINOSA</i>BY ASCORBIC ACID ACTING SINGLY AND IN COMBINATION WITH ANTIMICROBIALS: IN‐VITRO AND IN‐VIVO STUDIES

Rawal, B. D.; McKay, Geoffrey A.; Blackhall, Margaret I.

doi:10.5694/j.1326-5377.1974.tb50784.x

Cited by 19 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, this will increase the amount of ciprofloxacin that enters the cell wall and exerts its bactericidal activity against E. coli by inhibiting DNA gyrase and bacterial topoisomerase IV, which kills the bacteria and delays the development of resistance (Appelbaum and Hunter, 2000;Dijkmans et al, 2017). More ever, combination of ERY/Ascorbic showed a bacteriocidal effect only in 4 x MIC at 24 th hrs and bacteriostatic effect in 2 x MIC at 24 th hrs this in agreement with (Rawal, 1974(Rawal, , 1978 that showed the bactericidal effect of erythromycin against P. aeruginosa were found to be improved by ascorbic acid. While at low concentration there was no bacteriostatic nor bacteriocidal effect this is in agreement with (Wang et al, 1992) who showed that the effect of ascorbic acid on erythromycin is unknown.…”

Section: Time-kill Curve Kineticssupporting

confidence: 70%

Evaluation of Synergistic Antimicrobial Effect of Ascorbic Acid with Antibiotics Against E. coli O157 In Vitro

Ahmed,

Yahya

2023

AAVS

View full text Add to dashboard Cite

The present study was carried out to study the interaction between ascorbic acid and two antibiotic (ciprofloxacin and erythromycin) in-vitro and the in vitro. The research was included two experiments. The first one was to isolate and identify E. coli O157; E. coli sample was taken from a hospital, the sample was cultured on MacConkey agar, Sorbitol MacConkey agar, chrome agar, eosin methylene blue agar, then VITEK® 2 System was performed Data showed the sample was positive as a result of E. coli O157. The second experiment examined the pharmacodynamics of ascorbic acid in various states, including alone and in combination with ciprofloxacin and erythromycin. Results showed that the MIC of ascorbic acid (AA), ciprofloxacin (CIP), and erythromycin (ERY) against E. coli O157 was 16 mg/ml, 2 g/ml, and 256 g/ml, respectively, and the values of MBC by utilizing of Time kill curve were 32 mg/ml, 4 g/ml, and 512 g/ml for each of them, respectively. The pharmacodynamics-interactions within double combinations of ascorbic acid (AA) with ciprofloxacin (CIP) and erythromycin (ERY) against E. coli O157 isolate by micro dilution checkerboard assay showed that the combination of ascorbic acid with ciprofloxacin exhibited synergistic antibacterial effects through fractional inhibitory concentration (FIC index < 1) against tested isolate, while the combination of ascorbic acid with erythromycin exhibited antagonistic effects. Furthermore, time-kill analysis showed that ASCORBIC/CIP combination exhibited highest synergistic and bactericidal effect. It was determined that in vitro study against E. coli O157 in the treatment of urinary tract infection, the combination of ascorbic acid and ciprofloxacin was both more potent and safer than the combination of ascorbic acid and erythromycin. From this study concluded the combination of ciprofloxacin, and erythromycin against isolated E. coli showed that this microorganism is highly sensitive to ciprofloxacin and resistance to erythromycin.

show abstract

Section: Time-kill Curve Kineticssupporting

confidence: 70%

Evaluation of Synergistic Antimicrobial Effect of Ascorbic Acid with Antibiotics Against E. coli O157 In Vitro

Ahmed,

Yahya

2023

AAVS

View full text Add to dashboard Cite

show abstract

“…For example, AA supplementation effectively enhances animal resistance to endotoxin and tetanus toxin (58,59). Furthermore, researches reported that supplementation of AA is beneficial for many bacterial diseases, like Helicobacter pylori infection, P. aeruginosa infection, Streptococcus pneumoniae infection, bacterial peritonitis, and bacterial sepsis (60)(61)(62)(63)(64). In the field of veterinary medicine, for instance, Hamdy's group found that AA supplementation can improve the survival rate of sheep in spontaneous pneumonia, and Naresh's group demonstrated that supplementation of AA can improve the recovery rate of dairy cows with mastitis in clinic (65,66).…”

Section: Discussionmentioning

confidence: 99%

L-Ascorbic Acid Shapes Bovine Pasteurella multocida Serogroup A Infection

Zhao

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

Bovine Pasteurella multocida serogroup A (bovine PmA) is one of the most important pathogens causing fatal pneumonia in cattle. However, it is largely unknown how nutrition shapes bovine PmA infection. Here, we discovered that the infected lung held the highest bacterial density than other tissues during infection. By screening the different metabolites between high (lung)- and low (liver)-bacterial density tissues, the present work revealed that L-ascorbic acid and L-aspartic acid directly influenced bovine P. multocida growth. Interestingly, L-ascorbic acid, which is expressed at higher levels in the infected livers, inhibited bovine PmA growth as well as virulence factor expression and promoted macrophage bactericidal activity in vitro. In addition, ascorbic acid synthesis was repressed upon bovine PmA infection, and supplementation with exogenous L-ascorbic acid significantly reduced the bacterial burden of the infected lungs and mouse mortality. Collectively, our study has profiled the metabolite difference of the murine lung and liver during bovine PmA infection. The screened L-ascorbic acid showed repression of bovine PmA growth and virulence expression in vitro and supplementation could significantly increase the survival rate of mice and reduce the bacterial load in vivo, which implied that L-ascorbic acid could serve as a potential protective agent for bovine PmA infection in clinic.

show abstract

“…Reports of the effects of ascorbate (ASC) on bacteria are diverse and conflicting, and have appeared for many years. For instance, ASC (1.7–5.4 mM) was found to have a bactericidal effect upon several uropathogens in urine, independent of pH [ 3 ]; the minimal inhibitory concentration (MIC) of ASC upon clinical isolates of Pseudomonas aeruginosa was in the 18.7–1233 mM range [ 4 ], but MIC 50 and MIC 90 of ASC upon clinical isolates of P. aeruginosa were reported to be 1.8 mM and 3.6 mM, respectively (although this seems to have been assessed using non-neutralized ascorbic acid solutions [ 5 ]), and ASC MICs for Escherichia coli and P. aeruginosa “standard strains” were 34 and 45 mM, respectively [ 6 ]; Mycobacterium tuberculosis seems particularly susceptible to ASC, with a MIC of 1 mM (contrasted with MICs of 16 and 32 mM for P. aeruginosa and E. coli , respectively, and >32 mM for Staphylococcus aureus and Enterococcus faecalis [ 7 ]); 57 mM ASC inhibits the planktonic growth of Proteus mirabilis [ 8 ]; the MIC of ASC upon clinical isolates of Acinetobacter baumannii was in the 3–6 mM range (although, surprisingly, the MIC for reference strain ATCC 1506 was 0.045 mM [ 9 ]).…”

Section: Introductionmentioning

confidence: 99%

“…ASC interaction with antibiotics and antibiotic resistance has also been documented: ASC had synergic effect with sulfonamides, trimethoprim, chloramphenicol, ampicillin, erythromycin and colistin in checkerboard assays on P. aeruginosa [ 4 ]; a 1-mM ASC treatment eliminates penicillinase plasmids from S. aureus , and reduces the MIC of penicillin and tetracycline [ 10 , 11 ]; a triple combination of ASC, apo-transferrin and imipenem was effective against carbapenem-resistant A. baumannii [ 9 ]; biofilm formation by P. aeruginosa was inhibited by ASC at 11–34 mM concentrations [ 6 ] and at 0.2–2 mM (possibly non-neutralized ASC; and also diminished piperacillin, ceftazidime, ciprofloxacin and gentamicin MICs [ 5 ]); but 2 mM ascorbate reduced the biofilm inhibitory activity of aminoglycosides gentamicin and amikacin [ 8 ]; addition of 10 mM ASC decreased the MIC of some antibiotics (e.g., ampicillin, tetracycline) and increased the MIC of others (e.g., erythromycin, ciprofloxacin) when testing S. aureus , several Streptococcus spp., and E. coli [ 12 ]. In non-PubMed-indexed journals reports are even more disparate (e.g., [ 13 , 14 , 15 ]).…”

Section: Introductionmentioning

confidence: 99%

Ascorbate and Antibiotics, at Concentrations Attainable in Urine, Can Inhibit the Growth of Resistant Strains of Escherichia coli Cultured in Synthetic Human Urine

Amábile-Cuevas¹

2023

Antibiotics

View full text Add to dashboard Cite

There are conflicting reports on the antibacterial activity of ascorbate; all at concentrations much higher than the typical in human plasma, but that can be reached in urine. The effect of 10 mM ascorbate (in itself not inhibitory) along with antibiotics, was tested both in Mueller-Hinton broth (MHb) and in synthetic human urine (SHU), against resistant isolates of Escherichia coli from lower urinary infections. The activity of nitrofurantoin and sulfamethoxazole was higher in SHU than in MHb; minimal inhibitory concentrations (MICs) in SHU with ascorbate were below typical urinary concentrations. For other antibiotics, MICs were the same in MHb vs. SHU, with no effect of ascorbate in MHb; but in SHU with ascorbate, MICs of ciprofloxacin and gentamicin also went below reported urinary concentrations, with a lesser effect with norfloxacin and trimethoprim, and none with ampicillin. The effect of ascorbate was independent of oxygen and not related to the susceptibility of each strain to oxidative stress. Ascorbate oxidizes during incubation in SHU, and bacterial growth partially prevented oxidation. These results suggest that 10 mM ascorbate can enhance the inhibitory activity of antibiotics upon resistant strains in urine. Clinical experimentation with ascorbate–antibiotic combinations against urinary infections caused by resistant bacteria is warranted.

show abstract

INHIBITION OFPSEUDOMONAS ÆRUGINOSABY ASCORBIC ACID ACTING SINGLY AND IN COMBINATION WITH ANTIMICROBIALS: IN‐VITRO AND IN‐VIVO STUDIES

Cited by 19 publications

References 4 publications

Evaluation of Synergistic Antimicrobial Effect of Ascorbic Acid with Antibiotics Against E. coli O157 In Vitro

Evaluation of Synergistic Antimicrobial Effect of Ascorbic Acid with Antibiotics Against E. coli O157 In Vitro

L-Ascorbic Acid Shapes Bovine Pasteurella multocida Serogroup A Infection

Ascorbate and Antibiotics, at Concentrations Attainable in Urine, Can Inhibit the Growth of Resistant Strains of Escherichia coli Cultured in Synthetic Human Urine

Contact Info

Product

Resources

About